Accès gratuit
Numéro
Med Sci (Paris)
Volume 32, Numéro 4, Avril 2016
Page(s) 387 - 393
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20163204017
Publié en ligne 2 mai 2016
  1. Kaplan MH, Hufford MM, Olson MR. The development and in vivo function of T helper 9 cells. Nat Rev Immunol 2015 ; 15 : 295–307. [CrossRef] [PubMed]
  2. Schmitt E, Germann T, Goedert S, et al. IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J Immunol 1994 ; 153 : 3989–3996.
  3. Bassil R, Orent W, Olah M, et al. BCL6 controls Th9 cell development by repressing Il9 transcription. J Immunol 2014 ; 193 : 198–207. [CrossRef]
  4. Brustle A, Heink S, Huber M, et al. The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol 2007 ; 8 : 958–966. [CrossRef] [PubMed]
  5. Jabeen R, Goswami R, Awe O, et al. Th9 cell development requires a BATF-regulated transcriptional network. J Clin Invest 2013 ; 123 : 4641–4653. [CrossRef] [PubMed]
  6. Staudt V, Bothur E, Klein M, et al. Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity 2010 ; 33 : 192–202. [CrossRef] [PubMed]
  7. Chang HC, Sehra S, Goswami R, et al. The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol 2010 ; 11 : 527–534. [CrossRef] [PubMed]
  8. Goswami R, Kaplan MH. Gcn5 is required for PU.1-dependent IL-9 induction in Th9 cells. J Immunol 2012 ; 189 : 3026–3033. [CrossRef]
  9. Yang XO, Zhang H, Kim BS, et al. The signaling suppressor CIS controls proallergic T cell development and allergic airway inflammation. Nat Immunol 2013 ; 14 : 732–740. [CrossRef] [PubMed]
  10. Veldhoen M, Uyttenhove C, van Snick J, et al. Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 2008 ; 9 : 1341–1346. [CrossRef] [PubMed]
  11. Dardalhon V, Awasthi A, Kwon H, et al. IL-4 inhibits TGF-beta-induced Foxp3+ T cells and together with TGF-beta, generates IL-9+ IL-10+ Foxp3- effector T cells. Nat Immunol 2008 ; 9 : 1347–1355. [CrossRef] [PubMed]
  12. Tamiya T, Ichiyama K, Kotani H, et al. Smad2/3 and IRF4 play a cooperative role in IL-9-producing T cell induction. J Immunol 2013 ; 191 : 2360–2371. [CrossRef]
  13. Wang W, Wang X, Chun J, et al. Inflammasome-independent NLRP3 augments TGF-beta signaling in kidney epithelium. J Immunol 2013 ; 190 : 1239–1249. [CrossRef]
  14. Kim IK, Kim BS, Koh CH, et al. Glucocorticoid-induced tumor necrosis factor receptor-related protein co-stimulation facilitates tumor regression by inducing IL-9-producing helper T cells. Nat Med 2015 ; 21 : 1010–1017. [CrossRef] [PubMed]
  15. Park J, Li H, Zhang M, et al. Murine Th9 cells promote the survival of myeloid dendritic cells in cancer immunotherapy. Cancer Immunol Immunother 2014 ; 63 : 835–845. [CrossRef] [PubMed]
  16. Jager A, Dardalhon V, Sobel RA, et al. Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J Immunol 2009 ; 183 : 7169–7177. [CrossRef]
  17. Vegran F, Berger H, Boidot R, et al. The transcription factor IRF1 dictates the IL-21-dependent anticancer functions of TH9 cells. Nat Immunol 2014 ; 15 : 758–766. [CrossRef] [PubMed]
  18. Wong MT, Ye JJ, Alonso MN, et al. Regulation of human Th9 differentiation by type I interferons and IL-21. Immunol Cell Biol 2010 ; 88 : 624–631. [CrossRef] [PubMed]
  19. Ma L, Xue HB, Guan XH, et al. Possible pathogenic role of T helper type 9 cells and interleukin (IL)-9 in atopic dermatitis. Clin Exp Immunol 2014 ; 175 : 25–31. [CrossRef] [PubMed]
  20. Longphre M, Li D, Gallup M, et al. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J Clin Invest 1999 ; 104 : 1375–1382. [CrossRef] [PubMed]
  21. Forbes EE, Groschwitz K, Abonia JP, et al. IL-9- and mast cell-mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med 2008 ; 205 : 897–913. [CrossRef] [PubMed]
  22. Kearley J, Buckland KF, Mathie SA, Lloyd CM. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway. Am J Respir Crit Care Med 2009 ; 179 : 772–781. [CrossRef] [PubMed]
  23. Borish L, Aarons A, Rumbyrt J, et al. Interleukin-10 regulation in normal subjects and patients with asthma. J Allergy Clin Immunol 1996 ; 97 : 1288–1296. [CrossRef] [PubMed]
  24. Gerlach K, Hwang Y, Nikolaev A, et al. TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol 2014 ; 15 : 676–686. [CrossRef] [PubMed]
  25. Singh TP, Schon MP, Wallbrecht K, et al. Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS One 2013 ; 8 : e51752. [CrossRef] [PubMed]
  26. Zhou Y, Sonobe Y, Akahori T, et al. IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol 2011 ; 186 : 4415–4421. [CrossRef]
  27. Kara EE, Comerford I, Bastow CR, et al. Distinct chemokine receptor axes regulate Th9 cell trafficking to allergic and autoimmune inflammatory sites. J Immunol 2013 ; 191 : 1110–1117. [CrossRef]
  28. Anuradha R, George PJ, Hanna LE, et al. IL-4-, TGF-beta-, and IL-1-dependent expansion of parasite antigen-specific Th9 cells is associated with clinical pathology in human lymphatic filariasis. J Immunol 2013 ; 191 : 2466–2473. [CrossRef]
  29. Faulkner H, Humphreys N, Renauld JC, et al. Interleukin-9 is involved in host protective immunity to intestinal nematode infection. Eur J Immunol 1997 ; 27 : 2536–2540. [CrossRef] [PubMed]
  30. Faulkner H, Renauld JC, Van Snick J, Grencis RK. Interleukin-9 enhances resistance to the intestinal nematode Trichuris muris. Infect Immun 1998 ; 66 : 3832–3840. [PubMed]
  31. Licona-Limon P, Henao-Mejia J, Temann AU, et al. Th9 cells drive host immunity against gastrointestinal worm infection. Immunity 2013 ; 39 : 744–757. [CrossRef] [PubMed]
  32. Purwar R, Schlapbach C, Xiao S, et al. Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med 2012 ; 18 : 1248–1253. [CrossRef] [PubMed]
  33. Lu Y, Hong S, Li H, et al. Th9 cells promote antitumor immune responses in vivo. J Clin Investig 2012 ; 122 : 4160–4171. [CrossRef]
  34. Kruger-Krasagakes S, Krasagakis K, Garbe C, et al. Expression of interleukin 10 in human melanoma. Br J Cancer 1994 ; 70 : 1182–1185. [CrossRef] [PubMed]
  35. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2001 ; 2 : 25–31. [CrossRef]
  36. Liu JQ, Li XY, Yu HQ, et al. Tumor-specific Th2 responses inhibit growth of CT26 colon-cancer cells in mice via converting intratumor regulatory T cells to Th9 cells. Sci Rep 2015 ; 5 : 10665. [CrossRef] [PubMed]
  37. Noelle RJ, Nowak EC. Cellular sources and immune functions of interleukin-9. Nat Rev Immunol 2010 ; 10 : 683–687. [CrossRef] [PubMed]
  38. Lu Y, Hong B, Li H, et al. Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci USA 2014 ; 111 : 2265–2270. [CrossRef]
  39. Fang Y, Chen X, Bai Q, et al. IL-9 inhibits HTB-72 melanoma cell growth through upregulation of p21 and TRAIL. J Surg Oncol 2015 ; 111 : 969–974. [CrossRef] [PubMed]
  40. Lemoli RM, Fortuna A, Tafuri A, et al. Interleukin-9 in human myeloid leukemia cells. Leuk Lymphoma 1997 ; 26 : 563–573. [CrossRef] [PubMed]
  41. Hoelzinger DB, Dominguez AL, Cohen PA, Gendler SJ. Inhibition of adaptive immunity by IL9 can be disrupted to achieve rapid T-cell sensitization and rejection of progressive tumor challenges. Cancer Res 2014 ; 74 : 6845–6855. [CrossRef]
  42. Davis MR, Zhu Z, Hansen DM, et al. The role of IL-21 in immunity and cancer. Cancer letters 2015 ; 358 : 107–114. [CrossRef] [PubMed]
  43. Croce M, Rigo V, Ferrini S. IL-21: a pleiotropic cytokine with potential applications in oncology. J Immunol Res 2015 ; 2015 : 696578. [CrossRef] [PubMed]
  44. Julia V, Staumont-Salle D, Dombrowicz D. Rôle de la fractalkine/CX3CL1 et de son récepteur CX3CR1 dans les pathologies allergiques. Med Sci (Paris) 2016 ; 32 : 260–266. [CrossRef] [EDP Sciences] [PubMed]
  45. Teillaud JL. Quand les anticorps rencontrent l’immunité antitumorale : fin de partie pour la cellule cancéreuse ? Med Sci (Paris) 2015 ; 31 : 707–708. [CrossRef] [EDP Sciences] [PubMed]
  46. Teillaud JL. L’homme qui a fait sauter le verrou de la réponse immune adaptative anti-tumorale. Med Sci (Paris) 2016 ; 32 : 121–122. [CrossRef] [EDP Sciences] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.